Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monotherapy for adults with previously treated advanced pancreatic cancer carrying a KRAS G12C mutation.
The designation is based on preliminary results from the Phase 1/2 LOXO-RAS-20001 study evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumours, including pancreatic cancer, and is intended to accelerate the drug's development and regulatory review.
Lilly said there are currently no approved therapies specifically targeting KRAS G12C-mutant pancreatic cancer, a rare form of the disease associated with poor outcomes.
Olomorasib is also being evaluated in multiple clinical studies, including the pivotal SUNRAY-01 and SUNRAY-02 trials in KRAS G12C-mutant non-small cell lung cancer.
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
bioMérieux files FDA application for rapid vaginitis diagnostic panel
Racura Oncology doses first patient in Phase 1 lung cancer trial
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer